Sanford-Burnham Medical Research Institute (SBMRI) is an independent nonprofit research and graduate degree-granting institute located in La Jolla, CA, that conducts laboratory-based biomedical research funded primarily through NIH grants. The mission of the SBMRI Cancer Center is to be a national leader in the effort to overcome cancer as a cause of human suffering and death. Our vision is to make paradigm-shifting discoveries that will underlie novel therapeutic modalities by creating, translating, and disseminating exceptional cancer basic science. We will attain this by: 1. Conducting state-of-the-art, multidisciplinary basic research into the causes, prevention, and treatment of cancer. 2. Advancing our discoveries into early preclinical development for the benefit of cancer patients everywhere. 3. Educating and training the next generation of cancer scientists. The CCSG application details our plans for advancing our early translational cancer research capabilities that include basic cancer discovery (novel gene targets and mechanisms), an area of long-standing exceptional strength at SBMRI Cancer Center. Advancing our scientific discoveries will take place through several platforms, including small-molecule-based drug discovery, an area where we have significant technical capabilities and experience, and early preclinical therapeutic development, a growing strength. The Cancer Center is organized around three programs that encompass the cancer continuum: Tumor Initiation and Maintenance, Cell Death and Survival Networks, and Tumor Microenvironment and Metastasis, each with three sub-themes based on the hallmarks of cancer. We describe 9 Shared Resources and a new developing Shared Resource, Cancer Metabolism, that are critical for achieving the scientific goals of the Programs with which they are tightly interwoven. We describe the past use of CCSG Developmental funds for supporting the recruitment of new faculty, collaborative translational pilot projects driven by Center investigators, and therapeutic development pilot projects through a new STRIVE program. We also describe the San Diego National Cancer Institute Centers Council (C3), a new collaborative initiative between the 3 San Diego NCI-designated Cancer Centers, SBMRI, UCSD and the Salk Institute, leveraging the unique skills and resources of each Center for the treatment, and ultimate cure of cancer. The application highlights the progress made towards achieving our vision through multi-level strategic planning and evaluation, investments, recruitments, collaborations, organizational changes, and research accomplishments. Situated in San Diego, the fifth most populous county and the second largest life sciences cluster in the US, SBMRI Cancer Center is poised to achieve its vision by leveraging its scientific strengths through collaborations with academic and private sector investigators locally, nationally and internationally.

Public Health Relevance

? OVERALL COMPONENT Sanford-Burnham Medical Research Institute (SBMRI) is an independent nonprofit research and graduate degree-granting institute located in La Jolla, CA, that conducts laboratory-based biomedical research. The SBMRI Cancer Center's vision is to make paradigm-shifting discoveries that will underlie novel therapeutic modalities by creating, translating, and disseminating exceptional cancer basic science. This will be achieved by conducting cutting-edge, multidisciplinary basic research, advancing our discoveries into early pre-clinical development, and educating and training the next generation of cancer scientists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA030199-38
Application #
9689953
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-05-01
Project End
2020-04-30
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
38
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sanford Burnham Prebys Medical Discovery Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Wei, Yang; Toth, Julia I; Blanco, Gabrielle A et al. (2018) Adapted ATPase domain communication overcomes the cytotoxicity of p97 inhibitors. J Biol Chem 293:20169-20180
Tinoco, Roberto; Carrette, Florent; Henriquez, Monique L et al. (2018) Fucosyltransferase Induction during Influenza Virus Infection Is Required for the Generation of Functional Memory CD4+ T Cells. J Immunol 200:2690-2702
Wonder, Emily; Simón-Gracia, Lorena; Scodeller, Pablo et al. (2018) Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo. Biomaterials 166:52-63
Limpert, Allison S; Lambert, Lester J; Bakas, Nicole A et al. (2018) Autophagy in Cancer: Regulation by Small Molecules. Trends Pharmacol Sci 39:1021-1032
Fujita, Yu; Khateb, Ali; Li, Yan et al. (2018) Regulation of S100A8 Stability by RNF5 in Intestinal Epithelial Cells Determines Intestinal Inflammation and Severity of Colitis. Cell Rep 24:3296-3311.e6
Scully, Kathleen M; Lahmy, Reyhaneh; Signaevskaia, Lia et al. (2018) E47 Governs the MYC-CDKN1B/p27KIP1-RB Network to Growth Arrest PDA Cells Independent of CDKN2A/p16INK4A and Wild-Type p53. Cell Mol Gastroenterol Hepatol 6:181-198
Borlido, Joana; Sakuma, Stephen; Raices, Marcela et al. (2018) Nuclear pore complex-mediated modulation of TCR signaling is required for naïve CD4+ T cell homeostasis. Nat Immunol 19:594-605
Follis, Ariele Viacava; Llambi, Fabien; Kalkavan, Halime et al. (2018) Regulation of apoptosis by an intrinsically disordered region of Bcl-xL. Nat Chem Biol 14:458-465
Pathria, Gaurav; Scott, David A; Feng, Yongmei et al. (2018) Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J 37:
Sun, Younguk; Chen, Bo-Rui; Deshpande, Aniruddha (2018) Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. Front Oncol 8:41

Showing the most recent 10 out of 599 publications